Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924053 | 0.80 | PSMB5 (0.38) | PSMB5GAAHTTALDH1A1KDM4E | |
| SCHEMBL18924125 | 0.79 | PSMB5 (0.41) | PSMB5MTNR1AMTNR1BGAAHTT | |
| SCHEMBL17570904 | 0.79 | PSMB5 (0.41) | PSMB5MTNR1AMTNR1BGAAHTT | |
| SCHEMBL1296672 | 0.76 | ADRB2 (0.44) | GAAALDH1A1POLBMAPTTSHR | |
| SCHEMBL20882707 | 0.73 | GAA (0.46) | PSMB5GAAALDH1A1KMT2ATSHR | |
| SCHEMBL18924054 | 0.72 | GAA (0.39) | PSMB5GAAALDH1A1KMT2APOLB | |
| SCHEMBL2576766 | 0.72 | KMT2A (0.44) | PSMB5GAAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2576767 | 0.72 | KMT2A (0.44) | PSMB5GAAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL16825248 | 0.70 | GAA (0.51) | GAAHTTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2576721 | 0.69 | MTNR1A (0.46) | PSMB5MTNR1AMTNR1BGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3189056-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885MTNR1A 340/4885MTNR1B 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.